Lung Cancer

Patients with the disease reported increased feelings of stigmatization, and results also showed that patients are viewed or treated differently than those with other cancer types.

Long-term opioid use is more prevalent among patients treated with invasive surgical techniques for early-stage non-small cell lung cancer than those who undergo minimally-invasive surgery.

While the living rooms take place in the ALCF's California headquarters, people around the world can tune in to the live stream, where they can participate and ask questions as if they were actually there.

The Food and Drug Administration (FDA) has approved Vizimpro (dacomitinib) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).

The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory and anxiety.

Patient-caregiver communities focused on non-small cell lung cancer with genomic alterations offer support, awareness and education to help accelerate research in this space.

With new therapies that can target specific genetic mutations in patients with lung cancer, testing the tumor’s makeup is becoming increasingly important, according to Joshua Bauml, M.D.

From an inaugural gathering in 2009 that attracted approximately 700 people, the Life and Liberty event has grown in size each year, with more than 4,000 patients in attendance at last September’s celebration. Organizers said about 6,000 were there this year.

An expert discusses tips on how patients with cancer can manage their "scanxiety."

The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

The researchers found that the trial that led to the guidelines – which recommend screening based on age and smoking history – did not include fair representation from all groups across the nation.

Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.

The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.

This is the first approval in the small cell lung cancer space in nearly two decades.

Caring for a young person with cancer can be a challenge, explains Nancy Bell.

In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

Clinical trials are starting to focus more on the tumor's genetic makeup than the tumor's location.

Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions.

When first diagnosed with lung cancer, some doctors told Bonnie J. Addario that there was nothing that they could do for her. Now, 14 years later, she has spent over a decade helping others with the disease through her Bonnie J. Addario Lung Cancer Foundation.